More

In a special Oval Office address, President Obama laid out how to fight terrorism, with freedom.

In just his third time addressing the country from the Oval Office, Obama set out to calm a country on edge.

In a special Oval Office address, President Obama laid out how to fight terrorism, with freedom.

On Sunday night, President Obama addressed the nation to discuss last week's attack in San Bernardino and the broader threat of terrorism. In his 13-minute prepared remarks, the president outlined the administration's ongoing strategy to take on ISIS.

"As commander-in-chief, I have no greater responsibility than to the safety of the American people."

But what stood out most in his speech was the amount of time the president dedicated to reinforcing one of the most core American values: religious freedom. While both the husband and wife who carried out the San Bernardino terrorist attacks were Muslim, the president urged the American people to resist the urge to ascribe the motivations of the attackers to Muslim-Americans as a whole.


In the first half of tonight's speech, President Obama unveiled a four-point plan to fight terrorism, but what he said after that was just as important. Photo by Saul Loeb-Pool/Getty Images.

His message was especially important since anti-Islam rhetoric has grown increasingly hostile after the attacks in Paris and San Bernardino.

And it seems to be having a very real and dangerous effect.

Since the Paris attacks, the rate at which London Muslims have been physically attacked has tripled.

Last month, armed "protesters" began keeping watch outside an Irving, Texas, Islamic Center, with the goal of stopping the "Islamization of America."

On Friday, Liberty University President Jerry Falwell Jr., urged students to arm themselves so that they may "end those Muslims."

The truth, however, is that whatever ideology the attackers in Paris or San Bernardino subscribed to, it's not that of mainstream Muslims. Wrongly painting all Muslims as "terrorists" puts innocent lives at risk. It's important to not paint with too broad a brush, especially given the outpouring of support the Muslim community has shown for victims and their families.

Three Muslim women arrive at a candlelight vigil held at San Manuel Stadium in San Bernardino. Photo: Robyn Beck/AFP/Getty Images

This speech was a big deal. The Oval Office is typically reserved for only the most serious matters of national unity.

It's been the setting for huge moments in our history. It's where President Reagan discussed the Challenger disaster, where President Kennedy called on Congress to pass what would become the Civil Rights Act. This was only the third time President Obama addressed the nation from the Oval Office — the other two times in 2010 to discuss the BP oil spill and to announce the end of combat operations in Iraq.

That's how essential the topic of Sunday's speech was.

Oval Office addresses have been a rarity, especially during Obama's presidency. Photo by Saul Loeb-Pool/Getty Images.

It's an important conversation to have. Here are the best moments from the president's speech.

On religious freedom:

After the attacks in Paris, some politicians floated the idea that the U.S. should turn away Muslim refugees. The president publicly opposed that idea, and he renewed that sentiment again.

On the San Bernardino shooting:

While the president stressed that there's no indication the perpetrators of the San Bernardino shootings had any formal ties to terrorist organizations, they are terrorists, and what they did was an act of terrorism.

On gun control:

Prior to the San Bernardino attacks, the president called on Congress to block people on the terrorism watch list from purchasing guns. During his speech, he renewed that call. Last week, the Senate blocked that move.

On American values:

"The values that we are fighting against ISIL for are precisely that we don't discriminate against people because of their faith," Obama said after last month's attacks in Paris. "We don't kill people because they're different than us.

That's what separates us from them. And we don't feed that kind of notion that somehow Christians and Muslims are at war."

We need to be strong, and we cannot give in to fear.

You can watch President Obama's full address below.

For John Shults and Joy Morrow-Nulton, the COVID-19 pandemic brought more than just health threats and lockdown woes. For the two 95-year-olds, it also held something remarkable—another chance at romance.

Both Shults and Morrow-Nulton had been married twice and widowed twice, but they were determined to find love again. They met in May of 2019, brought together by Morrow-Nulton's 69-year-old son, John Morrow.

"She was cute, I'll tell you that," Shultz told the New York Times of their first meeting. "And she was smart and she had a delightful sense of humor. And she smiled at me."

Shultz asked her to lunch a few more times before it became crystal clear to Morrow-Nulton that he was on a mission to date her.

Keep Reading Show less

For John Shults and Joy Morrow-Nulton, the COVID-19 pandemic brought more than just health threats and lockdown woes. For the two 95-year-olds, it also held something remarkable—another chance at romance.

Both Shults and Morrow-Nulton had been married twice and widowed twice, but they were determined to find love again. They met in May of 2019, brought together by Morrow-Nulton's 69-year-old son, John Morrow.

"She was cute, I'll tell you that," Shultz told the New York Times of their first meeting. "And she was smart and she had a delightful sense of humor. And she smiled at me."

Shultz asked her to lunch a few more times before it became crystal clear to Morrow-Nulton that he was on a mission to date her.

Keep Reading Show less
True

Each year, an estimated 1.8 million people in the United States are affected by cancer — most commonly cancers of the breast, lung, prostate, and blood cancers such as leukemia. While not everyone overcomes the disease, thanks to science, more people are surviving — and for longer — than ever before in history.

We asked three people whose lives have been impacted by cancer to share their stories – how their lives were changed by the disease, and how they're using that experience to change the future of cancer treatments with the hope that ultimately, in the fight against cancer, science will win. Here's what they had to say.

Celine Ryan, 55, engineer database programmer and mother of five from Detroit, MI

Photo courtesy of Celine Ryan

In September 2013, Celine Ryan woke up from a colonoscopy to some traumatic news. Her gastroenterologist showed her a picture of the cancerous mass they found during the procedure.

Ryan and her husband, Patrick, had scheduled a colonoscopy after discovering some unusual bleeding, so the suspicion she could have cancer was already there. Neither of them, however, were quite prepared for the results to be positive -- or for the treatment to begin so soon. Just two days after learning the news, Ryan had surgery to remove the tumor, part of her bladder, and 17 cancerous lymph nodes. Chemotherapy and radiation soon followed.

Ryan's treatment was rigorous – but in December 2014, she got the devastating news that the cancer, once confined to her colon, had spread to her lungs. Her prognosis, they said, was likely terminal.

But rather than give up hope, Ryan sought support from online research, fellow cancer patients and survivors, and her medical team. When she brought up immunotherapy to her oncologist, he quickly agreed it was the best course of action. Ryan's cancer, like a majority of colon and pancreatic cancers, had been caused by a defect on the gene KRAS, which can result in a very aggressive cancer that is virtually "undruggable." According to the medical literature, the relatively smooth protein structure of the KRAS gene meant that designing inhibitors to bind to surface grooves and treat the cancer has been historically difficult. Through her support systems, Ryan discovered an experimental immunotherapy trial at the National Institutes of Health (NIH) in Bethesda, MD., and called them immediately to see if she was eligible. After months of trying to determine whether she was a suitable candidate for the experimental treatment, Ryan was finally accepted.

The treatment, known as tumor-infiltrating lymphocyte therapy, or TIL, is a testament to how far modern science has evolved. With this therapy, doctors remove a tumor and harvest special immune cells that are found naturally in the tumor. Doctors then grow the cells in a lab over the next several weeks with a protein that promotes rapid TIL growth – and once the cells number into the billions, they are infused back into the patient's body to fight the cancer. On April 1, 2015, Ryan had her tumor removed at the NIH. Two months later, she went inpatient for four weeks to have the team "wash out" her immune system with chemotherapy and infuse the cells – all 148 billion of them – back into her body.

Six weeks after the infusion, Ryan and Patrick went back for a follow-up appointment – and the news they got was stunning: Not only had no new tumors developed, but the six existing tumors in her lungs had shrunk significantly. Less than a year after her cell infusion, in April 2016, the doctors told Ryan news that would have been impossible just a decade earlier: Thanks to the cell infusion, Ryan was now considered NED – no evaluable disease. Her body was cancer-free.

Ryan is still NED today and continuing annual follow-up appointments at the NIH, experiencing things she never dreamed she'd be able to live to see, such as her children's high school and college graduations. She's also donating her blood and cells to the NIH to help them research other potential cancer treatments. "It was an honor to do so," Ryan said of her experience. "I'm just thrilled, and I hope my experience can help a lot more people."

Patrice Lee, PhD, VP of Pharmacology, Toxicology and Exploratory Development at Pfizer

Photo courtesy of Patrice Lee

Patrice Lee got into scientific research in an unconventional way – through the late ocean explorer Jacques Cousteau.

Lee never met Cousteau but her dreams of working with him one day led her to pursue a career in science. Initially, Lee completed an undergraduate degree in marine biology; eventually, her interests changed and she decided to get a dual doctoral degree in physiology and toxicology at Duke University. She now works at Pfizer's R&D site in Boulder, CO (formerly Array BioPharma), leading a group of scientists who determine the safety and efficacy of new oncology drugs.

"Scientists focused on drug discovery and development in the pharmaceutical industry are deeply committed to inventing new therapies to meet unmet needs," Lee says, describing her field of work. "We're driven to achieve new medicines and vaccines as quickly as possible without sacrificing safety."

Among the drugs Lee has helped develop during her career, including cancer therapies, she says around a dozen are currently in development, while nine have received FDA approval — an incredible accomplishment as many scientists spend their careers without seeing their drug make it to market. Lee's team is particularly interested in therapies for brain metastases — something that Lee says is a largely unmet need in cancer research, and something her team is working on from a variety of angles. "Now that we've had rapid success with mRNA vaccine technology, we hope to explore what the future holds when applying this technology to cancers," Lee says.

But while evaluating potential cancer therapies is a professional passion of Lee's, it's also a mission that's deeply personal. "I'm also a breast cancer survivor," she says. "So I've been on the other side of things and have participated in a clinical trial."

However, seeing how melanoma therapies that she helped develop have affected other real-life cancer patients, she says, has been a highlight of her career. "We had one therapy that was approved for patients with BRAF-mutant metastatic melanoma," Lee recalls. "Our team in Boulder was graced by a visit from a patient that had benefited from these drugs that we developed. It was a very special moment for the entire team."

None of these therapies would be available, Lee says without rigorous science behind it: "Facts come from good science. Facts will drive the development of new drugs, and that's what will help patients."

Chiuying "Cynthia" Kuk (they/them) MS, 34, third-year medical student at Michigan State University College of Human Medicine

Photo courtesy of Cynthia Kuk

Cynthia Kuk was just 10 years old when they had a conversation that would change their life forever.

"My mother, who worked as a translator for the government at the time, had been diagnosed with breast cancer, and after her chemotherapy treatments she would get really sick," Kuk, who uses they/them pronouns, recalls. "When I asked my dad why mom was puking so much, he said it was because of the medicine she was taking that would help her get better."

Kuk's response was immediate: "That's so stupid! Why would a medicine make you feel worse instead of better? When I'm older, I want to create medicine that won't make people sick like that."

Nine years later, Kuk traveled from their native Hong Kong to the United States to do exactly that. Kuk enrolled in a small, liberal arts college for their Bachelor's degree, and then four years later started a PhD program in cancer research. Although Kuk's mother was in remission from her cancer at the time, Kuk's goal was the same as it had been as a 10-year-old watching her suffer through chemotherapy: to design a better cancer treatment, and change the landscape of cancer research forever.

Since then, Kuk's mission has changed slightly.

"My mom's cancer relapsed in 2008, and she ended up passing away about five years after that," Kuk says. "After my mom died, I started having this sense of urgency. Cancer research is such that you work for twenty years, and at the end of it you might have a fancy medication that could help people, but I wanted to help people now." With their mother still at the forefront of their mind, Kuk decided to quit their PhD program and enter medical school.

Now, Kuk plans to pursue a career in emergency medicine – not only because they are drawn to the excitement of the emergency room, but because the ER is a place where the most marginalized people tend to seek care.

"I have a special interest in the LGBTQ+ population, as I identify as queer and nonbinary," says Kuk. "A lot of people in this community and other marginalized communities access care through the ER and also tend to avoid medical care since there is a history of mistreatment and judgement from healthcare workers. How you carry yourself as a doctor, your compassion, that can make a huge difference in someone's care."

In addition to making a difference in the lives of LGBTQ+ patients, Kuk wants to make a difference in the lives of patients with cancer as well, like their mother had.

"We've diagnosed patients in the Emergency Department with cancer before," Kuk says. "I can't make cancer good news but how you deliver bad news and the compassion you show could make a world of difference to that patient and their family."

During their training, Kuk advocates for patients by delivering compassionate and inclusive care, whether they happen to have cancer or not. In addition to emphasizing their patient's pronouns and chosen names, they ask for inclusive social and sexual histories as well as using gender neutral language. In doing this, they hope to make medicine as a whole more accessible for people who have been historically pushed aside.

"I'm just one person, and I can't force everyone to respect you, if you're marginalized," Kuk says. "But I do want to push for a culture where people appreciate others who are different from them."